Mavorixafor (trihydrochloride)
CAT:
804-HY-50101A-04
Size:
100 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Mavorixafor (trihydrochloride)
- CAS Number: 2309699-17-8
- UNSPSC Description: Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively.Mavorixafor trihydrochloride can be used for the study of WHIM syndrome[1].
- Target Antigen: CXCR; HIV
- Type: Reference compound
- Related Pathways: Anti-infection;GPCR/G Protein;Immunology/Inflammation
- Applications: COVID-19-anti-virus
- Field of Research: Infection; Endocrinology; Cancer
- Assay Protocol: https://www.medchemexpress.com/AMD-070-hydrochloride.html
- Purity: 99.75
- Solubility: DMSO : 150 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)
- Smiles: [H]Cl.[H]Cl.[H]Cl.NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3
- Molecular Weight: 458.86
- References & Citations: [1]Skerlj RT, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010 Apr 22;53(8):3376-88.|[2]Uchida D, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncol Rep. 2018 Jul;40(1):303-308.Oncol Rep. 2022 Apr;47(4):68.|Biosci Rep. 2023 Dec 22;43(12):BSR20230981.|Br J Haematol. 2022 Dec 19.|Cell Mol Life Sci. 2024 Mar 13;81(1):132.|Patent. US20220273751A1.|PLoS One. 2016 Mar 21;11(3):e0151765.
- Shipping Conditions: Room Temperature
- Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
- Clinical Information: Launched